AstraZeneca
	Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. For more information, visit http://www.merck.com/.
	MinuteClinic (www.minuteclinic.com) is the pioneer and largest provider of retail-based health care in the United States. A subsidiary of CVS Caremark Corporation, MinuteClinic launched the first retail clinics in the United States in 2000 and is the first provider to establish a national presence with more than 520 locations across the country in 25 states.  By creating a health care delivery model that responds to consumer demand, MinuteClinic makes access to high-quality medical treatment for common family illnesses easier for more Americans.  The company has generated more than one 2 million patient visits, with a 99 percent customer satisfaction rating.  For more information, visit http://www.minuteclinic.com/.
	Novo Nordisk is a global healthcare company with an 80-year history of innovation and achievement in diabetes care.  Novo Nordisk manufactures and markets a comprehensive portfolio of insulin analogs and delivery systems.  Novo Nordisk also has a leading position within such areas as hemostasis and growth hormone therapy.  For more information, visit http://www.novonordisk-us.com/.
	RediClinic is different.  Our clinicians are visionaries leading the way to a new healthcare destination.  We were founded to give patients more convenient and affordable access to healthcare.  Our model supports clinician autonomy guided by evidence-based practice with additional support from leading healthcare systems.  Our team of caring professionals provides treatment for over 30 conditions, and promotes better health in their communities through RediClinic’s wide range of preventive health services.  For more information, visit http://www.rediclinic.com/careers.asp.
sanofi-aventis US
	Sepracor Inc. is a research-based pharmaceutical company dedicated to Improving Health Through Innovation™.  We are focused on discovering, developing and commercializing differentiated pharmaceutical products that serve large and growing markets with unmet medical needs.  Our drug development program has yielded a portfolio of pharmaceutical products with an emphasis on the treatment of respiratory and central nervous system disorders, including the brands:  LUNESTA®, XOPENEX® Inhalation Solution, XOPENEX HFA® Inhalation Aerosol and BROVANA®.  Additionally, through our corporate development initiatives, Sepracor markets the brands OMNARIS™ Nasal Spray and ALVESCO® Inhalation Aerosol, for which we acquired U.S. distribution rights from Nycomed GmbH.  Sepracor has also established out-licensing agreements with Schering-Plough for CLARINEX®, sanofi-aventis for ALLEGRA® and UCB Pharma for XYZAL®/XUSAL™.  For more information, visit http://www.sepracor.com/.